Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Research into the management of MLL

Rob Pieters • 12 Sep 2018
SOHO 2018
Acute Lymphoblastic Leukemia Leukemia Azacitidine Blinatumomab Inotuzumab ozogamicin

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses current research and drug developments to treat mixed lineage leukemia (MLL) rearranged acute lymphoblastic leukemia (ALL). Prof. Pieters states that numerous epigenetic abnormalities were discovered in MLL rearranged ALL, hence the market for drugs to modify these abnormalities has expanded. He highlights a few drugs that are currently being studied including demethylating agents such as azacitidine as well as monoclonal antibodies blinatumomab and inotuzumab.

More from Rob Pieters

2:28
Updates on the survival rates of MLL treatments
Rob Pieters • 12 Sep 2018
1:26
Future directions for MLL therapy
Rob Pieters • 12 Sep 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals